Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement

Abstract

Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement, Acta Oncologica, 46:2, 262-264,

Primary plasma cell leukemia followed by testicular plasmacytoma

“…Bortezomib is a proteasome inhibitor successfully used for the therapy of multiple myeloma even in patients with extraosseous disease, now experimented in primary and secondary PCL. In this regard, the information are still limited [14][15][16][17], but recently Musto et al [17] described 12 PCL (8 primary and 4 secondary) treated with bortezomib-containing regimen, obtaining promising results, with an overall response rate of 92% (5 PR, 4 VGPR, 2 CR), and a median survival of 8 months. Despite the use of bortezomib, in our case, the disease rapidly spread, with the involvement of unusual sites.…”

Stringent Complete Remission of Primary Plasma Cell Leukemia with Reduced-dose Bortezomib, Lenalidomide and Dexamethasone: A Case Report and Review of the Literature

“…The VRD regimen currently used usually consists of 3-week cycles of bortezomib at a dose of 1.3 mg/m 2 (on days 1, 4, 8 and 11), lenalidomide at a dose of 25 mg (days [1][2][3][4][5][6][7][8][9][10][11][12][13][14] and dexamethasone (40 or 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12). However, peripheral neuropathy is one of the most critical toxicities of bortezomib and often leads to dose modification and drug discontinuation.…”

“…Both bortezomib and lenalidomide are approved for the treatment of advanced multiple myeloma. Recently, the efficacy of bortezomib was also observed in a series of patients with newly diagnosed or relapsed PCL (6)(7)(8). Some reports have suggested that lenalidomide is effective in patients with relapsed PCL (9-11).…”

Hemoglobin disorders in the developing world: A perspective from Sri Lanka

“…There are a small number of reports on the utilization of bortezomib for PPCL [10][11][12][13][14][15][16][17][18][19][20]. Published response rates to bortezomib combination therapy in PPCL are promising.…”